JOIN OUR LONG TERM VISION IN Tuberculosis research

Tuberculosis is a Pandemic

end TB

Tuberculosis (TB) is a global disease, found in every country in the world and with close to 30,000 people falling ill from it every single day, this preventable and curable infection is the leading infectious cause of death worldwide.  The growing resistance to existing treatments means the disease is becoming more deadly and difficult to treat, with more than a million cases of drug resistant TB reported in 2020.

Evotec is at the forefront of TB research, advancing a portfolio of drug discovery programmes and an innovative translational science platform to accelerate drug regimen development. Last year saw us help launch many new collaborations to develop novel regimens to treat all forms of TB.  A year later, COVID-19 has changed the world – but the need for new treatments for the 10 million people who develop TB each year is as urgent as ever. We continue working with our partners to #EndTB.

a growing network of partnerships

 
2018

Evotec is a member of the TB Drug Accelerator Programme aiming to develop new pre-clinical candidates with treatment shortening potential and provide proof-of-concept for a one-month three-drug regimen
2019

Bill & Melinda Gates Foundation supports Evotec with a $23.8 M grant to generate critical data for selecting best drug combinations for Phase II clinical trials
2019

Bill & Melinda Gates Foundation funds collaboration of the HZI/HIPS with Evotec to develop new drug approaches for treating TB
2020

Evotec joins the ERA4TB Consortium which brings together a multi-disciplinary team with proven expertise and capabilities in TB drug development to profile and progress anti-TB compounds up to completion of Phase I
2020

Evotec enters into a first-of-its-kind global collaboration with PAN-TB, that aims to accelerate the development of pan-TB drug regimens for the treatment of Tuberculosis

Read more here

 

View our scientific resources

  • The Tuberculosis Drug Accelerator at year 10: What have we learned?

  • Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis
 Download NowDownload Now
  • Bactericidal Disruption of Magnesium Metallostasis in Mycobacterium tuberculosis is Counteracted by Mutations in the Metal Ion Transporter CorA 
 Download Now
  • Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition
 Download Now
  • Cyclohexyl-Griselimycin is Active Against Mycobacterium Abscessusin Mice

 Download Now
  • Integrative Analysis of Human Macrophage Inflammatory Response Related to Mycobacterium Tuberculosis Virulence
 Download Now
  • ERA4TB Video

  • Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions

View Now

View Now
 

 

 

CONTACT US

Talk to our TB experts for any additional information or requirements: info@evotec.com